

ASX RELEASE

28 June 2021

AMPLIA AND GARVAN INSTITUTE ENTER INTO COLLABORATION AGREEMENT

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce it has now finalised and executed a Collaboration Agreement and a Research & Licence Agreement with the Garvan Institute of Medical Research (“Garvan”) in Sydney, Australia that was announced in March 2021. These Agreements define the structure of an ongoing collaborative research and clinical development program to be undertaken with Garvan which initially focuses on the use of Amplia’s FAK inhibitor, AMP945, to treat patients with pancreatic cancer.

The collaboration, which was forecast with the signing of a non-binding Term Sheet in March 2021, provides Amplia with access to Garvan’s research strength in FAK biology and its extensive clinical research network. Already, non-clinical studies conducted in the laboratory of Professor Paul Timpson, Cancer Research Theme Leader at Garvan, a world-renowned expert in FAK biology, have provided Amplia with valuable insights into the ability of AMP945 to inhibit fibrosis and significantly improve survival in an animal model of aggressive pancreatic cancer. The Company is incorporating these insights and using its access to Garvan’s clinical research network to assist with the design and planning of a Phase 2 clinical trial of AMP945 in patients with pancreatic cancer that is scheduled to commence later this year. The terms of the final Collaboration Agreement also provide for expansion into other therapeutic areas.

Amplia’s CEO and Managing Director, Dr John Lambert, commented that “It is very exciting for Amplia to be able to tap into the extensive experience in FAK biology, cancer biology, and clinical networks that are available at a globally-recognised research institute such as Garvan. We have already seen the benefits of this collaboration through the results of the non-clinical studies which we announced earlier this year. These studies have provided important insights into the biology of AMP945 and have further validated our decision to progress this promising drug into a Phase 2 clinical trial in pancreatic cancer patients.”

Professor Chris Goodnow, Garvan’s Executive Director noted that “At Garvan, we aim to translate our cancer research findings into better treatment options and improved clinical outcomes for patients. We are delighted to be working with Amplia in the development of its unique FAK inhibitors as potential new anti-fibrotic treatments for patients with pancreatic cancer or other fibrotic diseases.”

Under the terms of the Collaboration Agreement, which has an initial term of 2 years, Amplia will receive first rights to participate in research projects relating to the use of FAK inhibitors in combination with other therapeutic products for the treatment of cancer. Under the terms of the Research and Licence Agreement, Amplia agrees to fund studies of the use of AMP945 in combination with gemcitabine / Abraxane® for the treatment of cancer, with an initial focus on pancreatic cancer, and Amplia will receive first rights to new intellectual property arising from the collaboration.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information

Level 21, 90 Collins Street, Melbourne VIC 3000

Email info@ampliatx.com

www.ampliatx.com

Dr. John Lambert
CEO and Managing Director
john@ampliatx.com
www.ampliatx.com

About Garvan Institute of Medical Research

The Garvan Institute of Medical Research is a leading multi-disciplinary biomedical research institute in Sydney. With 600 of the world's brightest scientific minds working under one roof, collaborating across different areas of research and using the best technologies to investigate diseases, Garvan have revealed causes and treatments for diseases including diabetes, osteoporosis, cancer, immune deficiency and autoimmunity.

www.garvan.org.au

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and fibrosis and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. In addition, the company is pursuing the potential of its FAK inhibitors in pulmonary fibrosis.